PDCD1 and lymphoma: Current data suggest that lymphomas characterized by an immune-rich stroma and elevated PD-L1/PD-1 expression are more likely to benefit from immune checkpoint inhibition (ICI), whereas those exhibiting an immune-desert phenotype may instead require therapeutic strategies directed against specific oncogenic drivers.